The AASLD conference this year was awesome! There was so much information that it was mind boggling! This issue of the HCV Advocate newsletter is all about AASLD. In addition we have compiled all of our conference coverage (including the newsletter coverage) and put it into a Guide that provides one-stop shopping for everything AASLD.
In addition to the great news presented at AASLD, simeprevir (Olysio) was approved for the treatment of HCV genotype 1 – another important advancement in medications to treat HCV.
1. A Guide to AASLD 2013: We are pleased to offer our first ‘Guide’ to AASLD 2013, containing a whole bunch of important information about hepatitis C and HIV/HCV coinfection. Included in the guide is all of our coverage from AASLD including that from the December 2013 HCV Advocate newsletter.
2. HCV Advocate Newsletter: December, 2013
In This Issue:
Check out our new fact sheets and the prescribing information for simeprevir (Olysio).
Olysio (Simeprevir) –Easy C.
Olysio (Simeprevir) –Fact Sheet.
Olysio (Simeprevir) –Package Insert.
3. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B, including
Studies Find Hepatitis B Virus Can Mutate and Infect Even Immunized People
Hepatitis B Patients Appear to Be At Risk of Other Diseases
Experts: Do Not Rush to Treat HBV-Infected Children
Primary Care Doctors Essential in Treating Immigrants at Risk of Liver Cancer
Relapse Rate Low in Those Who Respond Well to Entecavir
Only 64% of U.S. Health Care Providers Are Immunized Against Hepatitis B
Studies Reveal Important Information about Hepatitis B in Women
Hepatitis B Risk in African Immigrants and African-Americans Studied
4 Easy B Fact Sheets —We have updated all of the Easy B fact sheets in the Diagnostic Tools & Markers, and Transmission / Prevention series.
5. HCV Advocate News & Pipeline Blog!
Be sure to check out the latest clinical trial postings at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.
Call 877-HELP-4-HEP line (877-435-7443). The helpline is open from 9:00am to 7:00pm Eastern Time.
and much, much more…..
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org
**Questions and Comments: Questions and/or comments can be directed to email@example.com
**To receive the eblast in your email inbox simply send an e-mail to: firstname.lastname@example.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.
Follow us on Twitter